Search by Drug Name or NDC
NDC 00002-2980-60 RETEVMO 80 mg/1 Details
RETEVMO 80 mg/1
RETEVMO is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Eli Lilly and Company. The primary component is SELPERCATINIB.
MedlinePlus Drug Summary
Selpercatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults that has spread to other parts of the body in adults. It is also used to treat a certain type of thyroid cancer in adults and children 12 years of age and older that has spread to other parts of the body. Selpercatinib is also used to treat another type of thyroid cancer that has spread to other parts of the body in adults and children 12 years of age and older who have been treated unsuccessfully with radioactive iodine. Selpercatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Related Packages: 00002-2980-60Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Selpercatinib
Product Information
| NDC | 00002-2980 |
|---|---|
| Product ID | 0002-2980_b0f8f174-6de2-4231-94c7-ae860ba286d8 |
| Associated GPIs | 21535779000140 |
| GCN Sequence Number | 081026 |
| GCN Sequence Number Description | selpercatinib CAPSULE 80 MG ORAL |
| HIC3 | V1Q |
| HIC3 Description | ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS |
| GCN | 48026 |
| HICL Sequence Number | 046525 |
| HICL Sequence Number Description | SELPERCATINIB |
| Brand/Generic | Brand |
| Proprietary Name | RETEVMO |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | selpercatinib |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 80 |
| Active Ingredient Units | mg/1 |
| Substance Name | SELPERCATINIB |
| Labeler Name | Eli Lilly and Company |
| Pharmaceutical Class | Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA213246 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00002-2980-60 (00002298060)
| NDC Package Code | 0002-2980-60 |
|---|---|
| Billing NDC | 00002298060 |
| Package | 60 CAPSULE in 1 BOTTLE (0002-2980-60) |
| Marketing Start Date | 2020-05-08 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |